OIPE CONT.	· · · · · · · ·	-1 mg 2	Approved for use through 04/30/2 It and Trademark Office; U.S. DEPARTME	ENT OF COMMERCE .
Under the Paperwork Reduction Act of		are required to respond to a collection Application Number	on of information unless it displays a valid	OMB control number.
TRANSMITTAL	•	Filing Date	April 11, 2001	
FORM		First Named Inventor	RAUCY, Judy	
(to be used for all correspondence after	r initial filing)	Art Unit	1634	
		Examiner Name	SHEINBERG, Monika	
Total Number of Pages in This Submiss	ion 5	Attorney Docket Number	PUR-00114.P.1.1	
	ENC	LOSURES (Check all that	t apply)	
Fee Transmittal Form Fee Attached Amendment/Reply After Final Affidavits/declaration(s Extension of Time Request Express Abandonment Reque Information Disclosure Statem Certified Copy of Priority Document(s) Response to Missing Parts/ Incomplete Application Response to Missing I under 37 CFR 1.52 or	Rema 1. Form 2. 2 Volu 3. Return		After Allowance Corto a Technology Cel Appeal Communicator of Appeals and Inter Appeal Communication (Appeal Notice, Brief, Proprietary Information Status Letter Other Enclosure(s) Identify below):	nter (TC) tion to Board rferences tion to TC Reply Brief)
Si	IGNATURE (OF APPLICANT, ATTORN	IEY, OR AGENT	
Firm David R. Pleston Regolo 39, 10 Individual Signature				

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DG 20034 on this date:

Typed or printed

Signature

Date

Oct 1, 2003

CERTIFICATE OF TRANSMISSION/MAILING

Date

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

PTO/SB/17 (01-03)
Approved for use through 04/30/2003. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE o a collection of information unless it displays a valid OMB control number.

Telephone 858-724-0375

2003

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERC Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

FEE TRANSMITTAL for FY 2003

Effective 01/01/2003. Patent fees are subject to annual revision.

Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$) 180.00

Name (Print/Type)

Signature

epond to a concellent of intermediate of the second second to a concellent of intermediate.						
Complete if Known						
Application Number	09/832,621					
Filing Date	April 11, 2001					
First Named Inventor	RAUCY, Judy					
Examiner Name	SHEINBERG, Monika					
Art Unit	1634					
Attorney Docket No.	PUR-00114.P.1.1					

METHOD OF PAYMENT (check all that apply)	FEE CALCULATION (continued)					
✓ Check Credit card Money Other None	e 3. ADDITIONAL FEES				S	
Deposit Account:	Large Entity Small Entity					
Denosit	Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid
Account 501321	1051	130	2051		Surcharge - late filing fee or oath	
Number Deposit Account David R. Preston	1052	50	2052		Surcharge - late provisional filing fee or	
Account Name	1053	130	1053	130	cover sheet Non-English specification	
The Commissioner is authorized to: (check all that apply)	1812		1812		For filing a request for ex parte reexamination	
Charge fee(s) indicated below Credit any overpayments	1804	920*	1804	_,	Requesting publication of SIR prior to	
Charge any additional fee(s) during the pendency of this application	,				Examiner action	
Charge fee(s) indicated below, except for the filing fee	1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
to the above-identified deposit account.	1251	110	2251	55	Extension for reply within first month	
FEE CALCULATION	1252	410	2252	205	Extension for reply within second month	ļ
1. BASIC FILING FEE Large Entity Small Entity	1253	930	2253	465	Extension for reply within third month	
Fee Fee Fee Fee Description Fee Paid	1254	1,450	2254	725	Extension for reply within fourth month	
Code (\$) Code (\$) 1001 750 2001 375 Utility filing fee	1255	1,970	2255	985	Extension for reply within fifth month	
1001 750 2001 375 Ottlifty filling fee	1401	320	2401	160	Notice of Appeal	
1002 330 2002 103 Design limit let	1402	320	2402		Filing a brief in support of an appeal	
1004 750 2004 375 Reissue filing fee	1403	280	2403	140	Request for oral hearing	
1005 160 2005 80 Provisional filing fee	1451	1,510	1451	1,510	Petition to institute a public use proceeding	<u> </u>
SUBTOTAL (1) (\$) 0.00	1452	110	2452	55	Petition to revive - unavoidable	
	1453	1,300	2453	650	Petition to revive - unintentional	
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE	1501	1,300	2501	650	Utility issue fee (or reissue)	<u> </u>
Extra Claims below Fee Paid	1502	470	2502		Design issue fee	
Total Claims 20** = X = X	1503	630	2503		5 Plant issue fee	
Claims Multiple Dependent	1460	130	1460	130	Petitions to the Commissioner	
	1807	50	180		Processing fee under 37 CFR 1.17(q)	190.00
Large Entity Small Entity Fee Fee Fee Fee Fee Description	1806	180	180		Submission of Information Disclosure Stmt	180.00
Code (\$) Code (\$)	8021	40	802	1 40	Recording each patent assignment per property (times number of properties)	
1202 18 2202 9 Claims in excess of 20	1809	750	280	9 375	Filing a submission after final rejection	
1201 84 2201 42 Independent claims in excess of 3	Į.				(37 CFR 1.129(a))	
1203 280 2203 140 Multiple dependent claim, if not paid	1810	750	281	0 375	5 For each additional invention to be examined (37 CFR 1.129(b))	
1204 84 2204 42 ** Reissue independent claims over original patent	1801	750	2801	375	5 Request for Continued Examination (RCE)	
1205 18 2205 9 ** Reissue claims in excess of 20 and over original patent	1802	900	1802	90	 Request for expedited examination of a design application 	
[m, 0, 00	Other	r fee (s _l	pecify) .	_		<u></u>
**or number previously paid, if greater; For Reissues, see above	*Red	uced by	y Basic	Filing F	Fee Paid SUBTOTAL (3) (\$) 180.	00
CHAMITTED BY			=		(Complete (if applicable)	

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Registration No.

(Attorney/Agent)

38,710

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.



Patent
Docket Number: PUR-00114.P.1.1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:)
Raucy) Examiner: Monika Sheinberg
Application No.: 09/832,621) Art Unit: 1634
Filed: April 11, 2001)
For: COMPOSITIONS AND)
METHODS FOR INDUCTION OF)
PROTEINS INVOLVED IN)
XENOBIOTIC METABOLISM)
Commissioner for Patents Alexandria VA 22313	
Sir:	

INFORMATION DISCLOSURE STATEMENT #3

Applicant respectfully submits this Information Disclosure Statement (IDS) after the mailing of a First Office Action on the merits under 37 C.F.R. §1.97(a)(3).

Applicant also submits a Form 1449, volumes of references cited on Applicant's Form 1449, and a check for \$180.00 to cover the IDS fee.

10/01/2008 REALINE | 600680. 0 092/2622 01 F001009 | 100.00 for

Information Disclosure Statement PUR-00114.P.1.1 Raucy

Please apply any charges not covered, or any credits, to <u>Deposit Account number</u> 501321 in the name of David R. Preston & Associates, having <u>Customer Number 24232</u>.

Respectfully submitted,

David R. Preston Reg. No. 38,710

Date: 30, 2003

David R. Preston & Associates 12625 High Bluff Drive Suite 205 San Diego, CA 92130

phone:

858.724.0375

facsimile:

858.724.0384



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

 Docket Number: PUR-00114.P.1.1	Application Number: 09/832,621
Applicant: Raucy	

Filing Date: Group Art Unit: April 11, 2001 1634

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	P1	5,071,773	12/10/91	Evans et al.			
	P2	5,298,429	3/29/94	Evans et al.			
	Р3	5,639,616	6/17/97	Liao et al.			
	P4	2002/022599	2/21/02	Synold et al.			
	P5	2002/0150915	10/17/02	Berkenstam et al.			
	P6	2002/0168623	11/14/02	Raucy			
	P7	2003/0064430	4/03/03	Evans et al.			

Examiner	Date	
Signature	Considered	



•	. FOREIGN PATENT DOCUMENTS								
EXAMINER		DOCUMENT	DATE C	000.,,,,,,,	CLASS	SUB-	Translation		
IN!TIAL		NUMBER			CLASS	YES	NO		
	F1	EP 0 644 267 A2	7/20/94	EPO					
	F2	WO 88/03168	5/5/88	PCT					
	F3	WO 94/27557	12/8/94	PCT					
	F4	WO 99/61622	12/2/99	PCT					
	F5	WO 01/20026 A2	3/22/01	PCT		·			
	F6	WO 01/71361 A1	9/27/01	PCT					
	F7	WO 01/97856 A2	12/27/01	PCT					
	F8	WO 02/24918 A1	3/28/02	PCT					
	F9	WO 02/36784 A1	5/10/02	PCT					
	F10	WO 02/088305 A2	11/7/02	PCT					
	F11	WO 02/094865 A1	11/28/02	PCT					
	F12	WO 02/095652 A1	11/28/02	PCT					

	Data	
Examiner	Date	
Signature	Considered	

		not 0 3 2003 m
		OTHER DOCUMENTS
	T **	(Inchiding Author, Title, Date, Pertinent Pages, Etc.)
EXAMINER INITIALS		CITATION
	D1	Barwick, Mol. Pharmacol., 50:10-16 (1996).
	D2	Dogra et al., Clinical Pharmacology and Physiology, 25: 1-9 (1998).
•	D3	Chen et al., Mol. Pharmacol., 64:316-324 (2003).
	D4	Cui et al., Journal of Pharmacology and Toxicological Methods, 47: 143-151 (2002).
	D5	Ferguson et al., Mol. Pharmacol. 62(3): 737-746 (2002).
	D6	Gonzalez et al., DNA, 7(2): 79-86 (1988).
	D7	Hakkola et al., Critical Reviews in Toxicology, 28(1): 35-72 (1998)
	D8	Hashimoto et al., Eur. J. Biochem., 218: 585-595 (1993).
	D9	Honkakoski et al., Ann. Med. 35(3): 172-182 (2003).
	D10	Kliewer et al., Cell, 92:73-82 (1998).
	D11	Kolars et al., Pharmacogenetics 4: 247-259 (1994).
	D12	Kovaleva et al., Biochemical and Biophysical. Research Communications 221: 129-132 (1996).
	D13	Moore et al., Molecular Endocrinology 16(5):977-986 (2002).
	D14	Ogg et al., Eur. J. of Drug Metabolism and Pharmacokinetics 22(4): 311-313 (1997).
	D15	Sakai and Takigami, Ind. Health 41: 205-214 (2003).
	D16	Smith et al., Xenobiotica, 28(12): 1129-1165 (1998).
	D17	Sonoda et al., Proc. Natl. Acad. Sci USA 99(21): 13801-13806 (2002).
	D18	Sulston and Waterston, Genome Res., 8(11): 1097-1108 (1998).
	D19	Xie et al., Proc Natl. Acad. Sci. USA 100(7): 4150-4155 (2003).
	D20	Yanagida et al., Molecular and Cellular Biology, 10(4): 1470-1475 (1990).
	D21	Yueh et al., J of Biological Chemistry 278(17): 15001-15006 (2003).

Examiner	Date	
Signature	Considered	